NEW YORK, April 16, 2020 (GLOBE NEWSWIRE) -- Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage biopharmaceutical company focused on enabling normal lives for patients with autoimmune diseases, today announced the closing of its previously announced underwritten public offering of 9,613,365 shares of its common stock, which includes the full exercise of the underwriters’ option to purchase 1,253,917 additional shares of common stock, at a price to the public of $14.50 per share. The aggregate gross proceeds to Immunovant from the offering were approximately $139.4 million, before deducting underwriting discounts and commissions and offering expenses. All of the shares of common stock were sold by Immunovant.
SVB Leerink, UBS Investment Bank, SunTrust Robinson Humphrey and Chardan acted as joint bookrunning managers for the offering. Nomura acted as the lead manager for the offering. LifeSci Capital LLC acted as the co-manager for the offering.
Registration statements relating to these securities have been filed with the U.S. Securities and Exchange Commission, and became effective on April 14, 2020. A copy of the final prospectus may be obtained from SVB Leerink LLC, Attention: Syndicate Department, One Federal Street, 37th Floor Boston, MA 02110, by telephone at 1-800-808-7525, ext. 6218, or by email at firstname.lastname@example.org; UBS Securities LLC, Attention: Prospectus Department, 1285 Avenue of the Americas, New York, NY 10019, by telephone at (888) 827-7275 or by email at email@example.com; SunTrust Robinson Humphrey, Inc., 3333 Peachtree Road NE, 9th Floor, Atlanta, GA 30326, Attention: Prospectus Department; email: firstname.lastname@example.org; or Chardan Capital Markets LLC, 17 State Street, 21st floor, New York, NY 10004.
This announcement is neither an offer to sell nor a solicitation of an offer to buy any of these securities, and shall not constitute an offer, solicitation, or sale in any jurisdiction in which such offer, solicitation, or sale is unlawful.
Immunovant, Inc. is a clinical-stage biopharmaceutical company focused on enabling normal lives for patients with autoimmune diseases. Immunovant is developing IMVT-1401, a novel, fully human anti-FcRn monoclonal antibody, as a subcutaneous injection for the treatment of autoimmune diseases mediated by pathogenic IgG antibodies.
John Strumbos, Ph.D., MBA
Vice President, Finance